The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model  Alasdair P. MacGowan, Karen E. Bowker, Mandy Wootton, H. Alan Holt  Clinical Microbiology and Infection  Volume 5, Issue 4, Pages 195-200 (April 1999) DOI: 10.1111/j.1469-0691.1999.tb00123.x Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Bactericidal effect of moxifloxacin, simulation dose of 400 mg every 24 h on H. influenzae: (a) strain NCTC 11931, β-lactamase negative, moxifloxacin MIC 0.06 mg/L; (b) strain 4718, β-lactamase positive, moxifloxacin MIC 0.06 mg/L; (c) strain 4797, cefuroxime resistant, moxifloxacin MIC 0.06 mg/L, and mutant strain 4797M, MIC 1.0 mg/L; (d) strain 5100, imipenem resistant, moxifloxacin MIC 0.06 mg/L and mutant strain 5100M, MIC 0.5 mg/L. Clinical Microbiology and Infection 1999 5, 195-200DOI: (10.1111/j.1469-0691.1999.tb00123.x) Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Bactericidal effect of moxifloxacin, simulated dose of 400 mg every 24 h on M. catarrhalis: (a) strain 9567, β-lactamase negative, moxifloxacin MIC 0.08 mg/L, and mutant, MIC 1.0 mg/L; (b) strain 9573, β-lactamase positive, moxifloxacin MIC 0.1 mg/L. Clinical Microbiology and Infection 1999 5, 195-200DOI: (10.1111/j.1469-0691.1999.tb00123.x) Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 3 Moxifloxacin antibacterial activity against H. influenzae and M. catarrhalis strains: relationship between AUBKC and AUC/MIC at 24 h and 48 h. Clinical Microbiology and Infection 1999 5, 195-200DOI: (10.1111/j.1469-0691.1999.tb00123.x) Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions